Observational study explores serum uric acid's link to organ damage in newly diagnosed hypertensive individuals, suggesting its potential as a biomarker.
A BSTRACT Background: Hypertension is a global health issue linked to target organ damage (TOD) in the heart, kidneys, and eyes. Serum uric acid (SUA) has been proposed as a potential marker for assessing TOD in hypertensive patients. This study explored the relationship between SUA levels and TOD in individuals newly diagnosed with Grade I or II essential hypertension. Methods: Conducted at AIIMS Bhubaneswar, the study included 80 patients—40 each with Grade I and II hypertension. SUA levels were measured and correlated with: • Left ventricular diastolic dysfunction (LVDD) via 2D echocardiography, • Microalbuminuria via urine albumin-creatinine ratio (ACR), • Hypertensive retinopathy via fundoscopy. Statistical tools included Kruskal-Wallis test, Spearman’s correlation, regression analysis, and ROC curve analysis. Results: SUA levels were significantly elevated in patients with advanced LVDD ( P < 0.001). A SUA threshold of ≥ 6.6 mg/dL predicted LVDD with 63% sensitivity and 91% specificity. SUA also showed a strong positive correlation with microalbuminuria ( r = 0.7, P < 0.001); levels ≥ 6.9 mg/dL predicted microalbuminuria (67% sensitivity, 89% specificity). A significant association was found between SUA and the severity of hypertensive retinopathy ( P < 0.001). Regression analysis confirmed SUA as an independent predictor of TOD, regardless of age, sex, and BMI. Conclusion: SUA is strongly associated with TOD in early-stage hypertension and may serve as a cost-effective biomarker for early detection of hypertensive complications. Further studies are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Dash et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: